J&J presses on with drug to prevent premature ejaculation

07/10/2007 | Wall Street Journal (free content), The

Other drugmakers have abandoned their search for a drug to prevent premature ejaculation, but Johnson & Johnson, whose first try was rejected by the FDA, is still in the hunt. The company intends to test its dapoxetine outside the U.S. and file for regulatory approval in Europe and Canada later this year. The FDA declined to approve it in 2005, questioning its medical benefit.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX